Lior Teitelbaum
Director/Board Member at Protekt Therapeutics Ltd.
Profile
Lior Teitelbaum was the founder of MindUP Ltd.
(founded in 2016) and held the title of Vice President-Business Development from 2016 to 2018.
Currently, Mr. Teitelbaum is a Senior Director at Johnson & Johnson Innovation - JJDC, Inc. since 2022.
Mr. Teitelbaum is also a Board of Director at FutuRx Ltd.
since 2019, a Director at ProteKt Therapeutics Ltd.
since 2019, and a Board member at A2i Therapeutics Ltd.
since 2021.
Previously, Mr. Teitelbaum worked as a Senior Director-Business Development at BioLineRx Ltd.
from 2012 to 2016, as a Director-Business Development & Marketing at Metacure Israel Ltd.
from 2010 to 2012, and as a Board Member at Pg Medical Systems Ltd.
from 2018 to 2019.
Mr. Teitelbaum holds an MBA from Tel-Aviv University, an undergraduate degree from The Hebrew University of Jerusalem (conferred in 2001), and a graduate degree from the Weizmann Institute of Science (conferred in 2004).
Lior Teitelbaum active positions
Companies | Position | Start |
---|---|---|
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Private Equity Investor | 2022-01-31 |
A2i Therapeutics Ltd.
A2i Therapeutics Ltd. Investment ManagersFinance A2i Therapeutics Ltd. is an Israeli AI-based drug-design company that aims to develop novel therapeutic modulators of the protein ADAR1, a key element of the innate immune system. The company is a joint venture of the FutuRx Incubator and Atomwise, utilizing the AtomNet® AI platform and FutuRx’s technology to translate extraordinary technologies to life-changing therapies. | Director/Board Member | 2020-12-31 |
Protekt Therapeutics Ltd.
Protekt Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Protekt Therapeutics Ltd. operates as a biopharmaceutical company. The firm develop a drug for enhancing the long-term memory of those suffering from mild cognitive impairment. The company is headquartered in Ness Ziona, Israel. | Director/Board Member | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | Corporate Officer/Principal | 2018-12-31 |
Former positions of Lior Teitelbaum
Companies | Position | End |
---|---|---|
Pg Medical Systems Ltd. | Director/Board Member | 2018-12-31 |
MindUP Ltd. | Founder | 2018-11-30 |
BIOLINERX LTD. | Private Equity Investor | 2015-04-30 |
Metacure Israel Ltd. | Sales & Marketing | 2011-12-31 |
Training of Lior Teitelbaum
Tel-Aviv University | Masters Business Admin |
The Hebrew University of Jerusalem | Undergraduate Degree |
Weizmann Institute of Science | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
BIOLINERX LTD. | Health Technology |
Private companies | 7 |
---|---|
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Finance |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | Finance |
Metacure Israel Ltd. | |
Protekt Therapeutics Ltd.
Protekt Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Protekt Therapeutics Ltd. operates as a biopharmaceutical company. The firm develop a drug for enhancing the long-term memory of those suffering from mild cognitive impairment. The company is headquartered in Ness Ziona, Israel. | Health Technology |
MindUP Ltd. | |
Pg Medical Systems Ltd. | |
A2i Therapeutics Ltd.
A2i Therapeutics Ltd. Investment ManagersFinance A2i Therapeutics Ltd. is an Israeli AI-based drug-design company that aims to develop novel therapeutic modulators of the protein ADAR1, a key element of the innate immune system. The company is a joint venture of the FutuRx Incubator and Atomwise, utilizing the AtomNet® AI platform and FutuRx’s technology to translate extraordinary technologies to life-changing therapies. | Finance |
- Stock Market
- Insiders
- Lior Teitelbaum